CASP1 and HIV-1 infection: We showed in the current work, that targeting inflammasome activation early after HIV-1 infection using the caspase-1 inhibitor VX-765 might represent a potential therapeutic strategy to improve CD4+ T cell homeostasis, and to reduce viral load and immune activation.